Three-year results from a multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer.

被引：0
|
作者：
Gradishar, WJ
Meza, L
Hill, T
Chen, YM
Varkey, JA
Hei, Y
Amin, B
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL 60611 USA
[2] SW Oncol Associates, Lafayette, LA USA
[3] Roche Labs, Nutley, NJ USA
[4] Mid Dakota Clin, Bismarck, MD USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [21] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase II study of semisynthetic paclitaxel in metastatic breast cancer
    Hudis, C
    Riccio, L
    Holmes, F
    Seidman, A
    Baselga, J
    Currie, V
    Fennelly, D
    Gilewski, T
    Moynahan, M
    Raptis, G
    Sklarin, N
    Surbone, A
    Uhlenhopp, M
    Maickel, N
    Yao, TJ
    Hellman, S
    Usakewicz, J
    Hortobagyi, G
    Norton, L
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) : 2198 - 2202
  • [23] Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
    Morris, Patrick G.
    Rota, Selene
    Cadoo, Karen
    Zamora, Stephen
    Patil, Sujata
    D'Andrea, Gabriella
    Gilewski, Theresa
    Bromberg, Jacqueline
    Dang, Chau
    Dickler, Maura
    Modi, Shanu
    Seidman, Andrew D.
    Sklarin, Nancy
    Norton, Larry
    Hudis, Clifford A.
    Fornier, Monica N.
    CLINICAL BREAST CANCER, 2018, 18 (05) : 387 - 394
  • [24] Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer
    Lee, K. S.
    Ro, J.
    Park, I. H.
    Kim, E. A.
    Nam, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
    Saeki T.
    Kimura T.
    Toi M.
    Taguchi T.
    Breast Cancer, 2006, 13 (1) : 49 - 57
  • [26] Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
    N Batista
    G Perez-Manga
    M Constenla
    A Ruiz
    F Carabantes
    J Castellanos
    M Gonzalez Barón
    K Villman
    M Söderberg
    J Ahlgren
    J Casinello
    P Regueiro
    A Murias
    British Journal of Cancer, 2004, 90 : 1740 - 1746
  • [27] Phase II study of paclitaxel and cisplatin for metastatic or recurrent esophageal cancer.
    Cho, SH
    Chung, IJ
    Yang, DH
    Byun, JR
    Kim, YK
    Lee, JJ
    Kim, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 326S - 326S
  • [28] Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
    Batista, N
    Perez-Manga, G
    Constenla, M
    Ruiz, A
    Carabantes, F
    Castellanos, J
    Barón, MG
    Villman, K
    Söderberg, M
    Ahlgren, J
    Casinello, J
    Regueiro, P
    Murias, A
    BRITISH JOURNAL OF CANCER, 2004, 90 (09) : 1740 - 1746
  • [29] Weekly paclitaxel and capecitabine in HER2-negative metastatic breast cancer (MBC): A multicenter GINECO randomized phase II comparing two paclitaxel-capecitabine schedules
    Lortholary, A.
    Hardy-Bessard, A. C.
    Bachelot, T.
    Dalivoust, P.
    de Rauglaudre, G.
    Alexandre, J.
    Bourgeois, H.
    Jaubert, D.
    Paraiso, D.
    Largillier, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
    Wist, E. A.
    Mjaaland, I.
    Lokkevik, E.
    Sommer, H. H.
    JOURNAL OF ONCOLOGY, 2012, 2012
12345